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ABSTRACT
To examine the role of ataxia-telangiectasia mutated (Atm) in telomere
function, we generated Atm and telomerase null mice (Atm/ mTR/
iG6 mice). These mice exhibited increased germ cell death and chromo-
some fusions compared with either Atm/ or mTR/ iG6 mice. Further-
more, the Atm/ mTR iG6 mice had a delayed onset and reduced
incidence of thymic lymphoma compared with Atm/ mice. The tumors
in the Atm/ mTR/ iG6 mice showed increased apoptosis and anaphase
bridges. Finally, lymphomas from Atm/ mTR/ iG6 mice were derived
from CD8 immature, single-positive T cells, whereas Atm/ lymphomas
were from CD4CD8 double-positive T cells. We propose that Atm
protects short telomeres and that Atm deficiency cooperates with short
telomeres, leading to increased cell death, decreased tumorigenesis, and
increased overall survival.
INTRODUCTION
Chromosomal rearrangement and instability can initiate tumor for-
mation. Cancer cells accumulate genetic changes because of loss of
checkpoint controls that normally ensure genomic integrity. Te-
lomeres protect chromosome ends from rearrangement, and loss of
telomere function may play an important role in fueling genomic
instability in cancer (1–5). In addition to promoting carcinogenesis,
telomere dysfunction can also limit tumor growth (4, 6, 7). Dysfunc-
tional telomeres activate cellular DNA damage responses and induce
cell cycle arrest, apoptosis, or senescence (3, 8, 9). The telomerase
null mouse, mTR/, shows progressive telomere shortening from the
first null generation, mTR/ G1, through the sixth generation of
interbreeding, mTR/ G6. Although the early generations, mTR/
G1–G3, show few abnormal phenotypes, the later-generation mice,
mTR/ G4–G6, have critically short telomeres and exhibit germ cell
apoptosis and infertility (10, 11), increased genomic instability, and
cancer predisposition (1–5). However, the underlying mechanisms of
response to dysfunctional telomeres are not yet understood but are
under active investigation.
A-T4 is a pleiotropic genetic disorder attributable to recessive
mutations in ATM (12, 13). It is characterized by cerebellar de-
generation, immunodeficiency, radiosensitivity, and cancer predis-
position, particularly lymphoid malignancies (14). The ATM fam-
ily of protein kinases, which includes ATR and their yeast
homologs Tel1 and Mec1/Rad3, plays a critical role in the cellular
response to DNA damage (15, 16). In the presence of DNA
damage, ATM and ATR phosphorylate downstream targets includ-
ing NBS, BRCA1, and p53 (15–19). In addition, ATM plays a
direct role in telomere maintenance. Loss of the ATM homolog
Tel1 in yeast leads to short telomeres (20 –24). Similarly, human
A-T cells have shorter telomeres than normal cells (25). Finally,
ATM may play a role in the cellular response to dysfunctional
telomeres. Overexpression of a dominant-negative form of the
telomere-binding protein TRF2 induces apoptosis in normal lym-
phocytes but not in lymphocytes from A-T patients (8).
To study the interplay between Atm and telomeres in telomere
function and tumorigenesis, we generated double-knockout mice with
short telomeres lacking Atm (Atm/ mTR/ iG6). Several lines of
Atm mutant mice have been described. Although these Atm mutant
mouse models recapitulate some features of the A-T patients, the
phenotypes of these mouse models vary (26–30), likely because of a
different genetic background and/or the different regions of the Atm
protein that were targeted. For example, the Atm/ mice generated
by Barlow et al. (26) on a 129S6/SvEvTac background develop
thymic lymphoma at 12–16 weeks of age. In contrast, the Atm mutant
mice Atmy/y generated by Borghesani et al. (29) on a 129Sv/C57BL6
background develop thymic lymphoma at much lower frequency with
a longer latency and have a median survival time of over 52 weeks.
The increased tumor latency in the latter case may be attributable to
the expression of a low level of mutant Atm mRNA with an intact
kinase domain in the Atmy/y mutant mice (29). Recently, Wong et al.
(31) crossed mTR/ mice onto Atmy/y mice and showed increased
cell death in bone marrow cell culture and gastrointestinal crypts in
the double-mutant mice. The incidence of thymic lymphoma was
decreased, but the survival of these mice was not changed.
We used the Atm mutant mouse model generated by Barlow et al.
(26) and adopted a different crossing scheme than Wong et al. (31).
Consistent with Wong et al. (31), we also found increased cell death
and reduced tumorigenesis in the double-mutant mice. Furthermore,
we observed the cooperative effect of Atm deficiency and short
telomeres on telomere dysfunction without extensive telomere short-
ening and an increased survival rate of double-mutant mice. We
examined possible mechanisms for the increased survival and found
that increased apoptosis and altered T-cell development contribute to
decreased tumor growth. Finally, our data suggest a role for Atm in
protecting short telomeres.
MATERIALS AND METHODS
Mice. mTR/ mice on a C57BL/6 background were generated as de-
scribed (10). Atm/ mice (The Jackson Laboratory) on a 129S6/SvEvTac
background (26) were mated to mTR/ mice to generate double-heterozygous
Atm/ mTR/ mice. The Atm/ mTR/ mice were intercrossed to gen-
erate Atm/ mTR/ and Atm/ mTR/ mice. Atm/ mTR/ iG6 mice
were generated by intergenerational crosses: Atm/ mTR/ mice were
crossed with mTR/ G4 mice to first generate Atm/ mTR/ iG5 mice.
These mice were then intercrossed to generate Atm/ mTR/ iG6 mice. The
Atm/ mTR/ iG6 and Atm/ mTR/ control mice are on the same
genetic background. Genotyping was done by PCR as described previously for
Atm (26) and mTR (32). All of the animals were maintained in a pathogen-free
facility, weighed every week, and checked every other day for signs of
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sickness. All mouse protocols were approved by the Institutional Care and Use
Committee at the Johns Hopkins University School of Medicine.
Histopathology Examination. When a mouse was sacrificed, its internal
organs were fixed in 10% formalin, and the rest of the mouse (skeleton, testis,
etc.) was fixed in Bouin’s solution. After being embedded in paraffin, 5-m
tissue sections were stained with H&E. The testis sections from 7- to 10-week-
old mice were examined and photographed using a Nikon inverted microscope
ECLIPSE TE300 with SPOT RT software (Diagnostic Instruments, Inc.). Over
100 tubules for each mouse were counted and classified into four categories
(normal, hypospermatogenesis, germinal arrest, and Sertoli cell only) by two
independent investigators. For the metastasis analysis, pathological diagnoses
were determined by two independent pathologists as a blind study.
Immunofluorescence and TUNEL Assay. Sections were deparaffinized
and hydrated as described previously (11). For GCNA1 and PCNA staining,
sections were stained after antigen retrieval with 1 mM EDTA with GCNA1
[undiluted; from G. C. Enders, University of Kansas, Kansas City, KS (38)],
followed by goat anti-rat IgM Cy3 (1:400; Jackson ImmunoResearch), PCNA
C-20 (1:100; Santa Cruz Biotechnology), followed by donkey anti-goat IgG
Cy3 (1:300; Jackson ImmunoResearch). TUNEL assay was performed using
the TUNEL kit (Roche) per the manufacturer’s procedure. Four low-power-
field pictures (200) were taken for each thymic lymphoma sample, and
TUNEL-positive cells were counted as a blind study.
Metaphase Preparation. Metaphases from spleen, thymus, and bone mar-
row were generated as described previously (33). In brief, splenocytes and
thymocytes were cultured in the presence of 5 g/ml ConA  20 g/ml
lipopolysaccharide, 750 ng/ml ionomycin  20 ng/ml phorbol myristate ace-
tate  10 units/ml of IL-2, respectively, for 48 h before being harvested for
metaphase preparation. To obtain bone marrow metaphases, mice received
injections of 0.1 ml of 0.5% colchicine (Sigma) for 45min before being
sacrificed. Bone marrow cells were obtained by flushing femurs and tibias with
fresh 75 mM KCl and incubated at 37°C for 15 min, followed by fixation four
times in fresh 3:1 methanol:glacial acetic acid.
Q-FISH and SKY. Q-FISH and SKY were performed on the same sets of
metaphases as described previously (34, 35). The analysis of chromosome
abnormalities (signal-free ends, translocations, fusions, and fragments) was
carried out as a blind study. To avoid counting chromosome fragments as
signal-free ends, the size of each chromosome lacking a telomere signal was
closely compared with its homolog using SKY. If the chromosome was shorter
than its homolog, the event was scored as a fragmentation and not as a
signal-free end. Each chromosome fusion was identified by SKY, and the
identity of all chromosome fusions was counted directly. In addition, to avoid
overestimating the clonal events, each specific chromosome fusion in a given
mouse was counted as one independent fusion event.
Kaplan-Meier Survival Curve. If the mouse dropped 20–40% of its body
weight in a 3-day interval and was motionless with dramatic trembling or other
signs of ill health, it was pronounced dead and evaluated by a complete
pathological examination.
Mitotic Figures and Anaphase Bridges. The measurement of mitotic
figures and the anaphase bridge index in the thymic lymphoma sections was
counted as a blind study by two independent investigators. A total of 10
high-power fields (600) were counted in each sample. Anaphase bridges
were defined as one or more lines spanning two separating anaphase poles.
BrdUrd Labeling. Mice at 7–10 weeks with no signs of sickness received
injections i.p. of BrdUrd (0.6 mg/10g body weight). One hour later, mice were
sacrificed, and bone marrow cells were flushed out from the femurs and tibias
using PBS. Cells were then fixed in cold 70% ethanol and stored overnight at
20°C. All of the following steps were done at room temperature. After being
treated with 50 units/ml of DNase (Roche) in 4.2 mM MgCl2/150 mM NaCl for
10 min, cells were incubated with anti-BrdUrd-FITC (BD PharMingen; no
dilution) for 30 min. Cells were then resuspended in 20 g/ml of 7-amino-
actinomycin D (Molecular Probes) for 30 min before being analyzed using the
CELLQUEST program (BD).
Flow Cytometric Analysis. Single-cell suspensions were prepared from
thymus or thymic lymphoma. After being washed once in PBS/2% BSA, cells
were stained with antibodies for 15 min at room temperature before the
analysis using the CELLQUEST program. Antibodies purchased from BD
PharMingen were as follows: CD4-FITC (RM4-5, 1:200), CD8-PE (53-6.7,
1:200), CD3-Cychrome (145-2C11, 1:200) or CD8-FITC (53-6.7, 1:200), TCR
-PE (H57-597, 1:200), CD4-Cychrome (RM4-5, 1:300).
RESULTS
Generation of Atm/ Mice with Short Telomeres Using Inter-
generational Cross. Because it is the shortest telomere that triggers
the cellular response to dysfunctional telomeres (33), we used an
intergenerational breeding method to introduce short telomeres into
Atm/ mice. Atm/ mTR/ mice were crossed with fourth gen-
eration (G4) mTR/ mice. The resulting progeny, Atm/ mTR/
iG5 (iG5 refers to the progeny of intergenerational crosses) were then
intercrossed to obtain Atm/ mTR/ iG6 and Atm/ mTR/ iG6
mice. The litter size resulting from this cross was only 2.8  1.4
pups/litter, which is significantly less than the 7.3  2.8 pups/litter for
the cross that generated Atm/ mTR/ iG5 mice (20 litters;
P  0.0001), indicating that short dysfunctional telomeres lead to a
loss of fertility as shown previously in the late-generation mTR/
mice (10).
Increased Germ Cell Death in the Atm/ mTR/ iG6 Mice.
To determine whether Atm is required for sensing telomere dysfunc-
tion, we examined germ cell death by assaying seminiferous tubule
morphology. Late-generation mTR/ mice show germ cell apoptosis
and seminiferous tubule atrophy (10, 11). In Atm/ mice, germ cells
arrest and accumulate at the leptotene-pachytene stage of meiosis (27,
36). In Atm/ mTR/ iG6 mice, 6.5% of the tubules were atrophic
and showed a Sertoli cell only phenotype (Ref. 37; Fig. 1, A and C).
Notably, there was a more severe phenotype in Atm/ mTR/ iG6
mice with 78% of the tubules lacking germ cells (Fig. 1, A and C). The
tubules that were not empty (22%) showed the germinal arrest
characteristic of Atm/ mTR/ mice (Fig. 1, A and C).
To further measure the extent of germ cell loss, we stained testis
sections for GCNA1, which is abundantly expressed in spermatogonia
and primary spermatocytes (38). There was a significant reduction in
GCNA1 staining in the Atm/ mTR/ iG6 mice compared with
wild-type mice and both single null mutant mice (Fig. 1, B and C). In
addition, staining for PCNA, a marker of mitotic and premeiotic
precursors (39), also showed extensive cell loss in Atm/ mTR/
iG6 (Fig. 1C). This tubule atrophy is not likely attributable to growth
defects of the Atm/ mTR/ iG6 mice because at 7–10 weeks, these
mice were of the same average size and grew at a rate similar to
Atm/ mTR/ iG6 mice (see Fig. 4B below). Therefore, unlike in
p53/ mTR/ late-generation mice (3), tubule atrophy was not
rescued by loss of Atm. We conclude that Atm is not essential for
germ cell death in response to short telomeres. A similar conclusion
was reached recently by Wong et al. (31) from their analysis of
apoptosis in bone marrow cell culture and intestinal crypts in Atmy/y
mTR/ mice. Furthermore, the significant increase in seminiferous
tubule atrophy in Atm/ mTR/ iG6 mice compared with either
Atm/ mTR/ or Atm/ mTR/ iG6 suggests that Atm defi-
ciency, together with short telomeres, accentuates telomere dysfunc-
tion.
Telomere-length Independent Cooperative Effect of Atm Defi-
ciency and Short Telomeres. To determine whether the increased
telomere dysfunction was telomere length dependent, we performed
Q-FISH on metaphase chromosome spreads from lymphocytes of
7–10 week old mice to measure the change in telomere length. There
was a slight reduction in average telomere length in Atm/ mTR/
compared with wild-type mice (Fig. 2B), consistent with the shorten-
ing seen in human A-T cells (25). Similarly, Atm/ mTR/ iG6
mice showed only a slight decrease in telomere length compared with
Atm/ mTR/ iG6 mice (Fig. 2D). Because the shortest telomere
triggers apoptosis (33), we quantitated the number of signal-free
chromosome ends in Atm/ mTR/ iG6 and Atm/ mTR/ iG6
mice. To distinguish chromosome fragments from signal-free ends,
we used FISH along with SKY. When fragments were eliminated, we
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found no significant difference in signal-free ends in Atm/ mTR/
iG6 lymphocytes compared with Atm/ mTR/ iG6 (P  0.46).
Although overall telomere length was not measured by Wong et al.
(31), they did report an increase in signal-free ends. The different
results may be attributable to the methods used to exclude chromo-
some fragments from the analysis or different Atm mutant mouse
models. Our study suggests that telomere shortening is not likely to
account for the increased telomere dysfunction in the Atm/ mTR/
iG6 mice.
Chromosome Instability Induced by Increased Telomere Dys-
function. Next, we examined the impact of Atm deficiency and short
telomeres on chromosomal rearrangements using SKY. A high rate of
chromosome fusions was seen in both Atm/ mTR/ iG6 and
Atm/ mTR/ iG6 animals (Table 1). In contrast, only one fusion
was present in the Atm single null mice (Table 1), suggesting that loss
of Atm alone does not lead to telomere dysfunction. Although the total
number of fusion events was higher in the Atm/ mTR/ iG6 mice
compared with the Atm/ mTR/ iG6 littermates (Table 1), this
increase was primarily attributable to the clonal expansion of two
fusion events, 12p;14p and 9p;14p (Fig. 3C). Although they are likely
clonal, these two fusions do not represent germ-line events because
they were not present in all metaphases from one given mouse (data
not shown). To avoid overrepresenting clonal fusion events, we quan-
titated the number of fusions between specific chromosomes in each
mouse as “independent fusion events” (Table 1 and Fig. 3C). The
spectrum of chromosomes involved in independent fusion events
differed significantly between Atm/ mTR/ iG6 and Atm/
mTR/ iG6 mice (Fig. 3C). Although all fusions in Atm/ mTR/
iG6 mice were p-arm-to-p-arm, the Atm/ mTR/ iG6 mice
showed both p-arm-to-p-arm and q-arm-to-q-arm fusions (Fig. 3 and
Table 1). In addition, many more independent chromosome ends were
involved in fusions in Atm/ mTR/ iG6 mice than in Atm/
mTR/ iG6 mice (Fig. 3C). Of 162 metaphases examined for both
genotypes, 25 different chromosome ends were involved in 25 inde-
pendent fusion events in Atm/ mTR/ iG6 mice, whereas only 8
chromosome ends were involved in 12 independent events in Atm/
mTR/ iG6 mice (Fig. 3C). Finally, there was an expected increase
in chromosome fragments and translocations in both Atm/ mTR/
and Atm/ mTR/ iG6 mice compared with the Atm/ mice
(Table 1), as has been documented previously in Atm/ mice (26,
40). Therefore, the increase in q;q fusions and the increased number
and change in the repertoire of the chromosomes involved in fusion in
Atm/ mTR/ iG6 mice suggest that loss of Atm function increases
telomere dysfunction of short telomeres.
Delayed and Reduced Incidence of Thymic Lymphoma in
Atm/ mTR/ iG6 Mice. We next determined how dysfunctional
telomeres affect tumorigenesis in the Atm background. The majority
of Atm/ mice from this mouse model typically develop thymic
lymphoma and die around 16 weeks of age (26–28, 41). In our colony,
the median survival time was 15 weeks for Atm/ mTR/ mice
(n  28; Fig. 4A). Strikingly, the Atm/ mTR/ iG6 mice had a
median survival time of 36 weeks (P  0.0009; Fig. 4A). In total,
47% of the Atm/ mTR/ iG6 mice (7 of 15) survived for over 44
weeks (Fig. 4A). Thymic lymphomas were found in 7 of 8 Atm/
mTR/ iG6 mice that died. A lymphoma of B-cell lineage was
observed in one Atm/ mTR/ iG6 mouse with an atrophic thymus
(Fig. 4A, asterisk). Thymic lymphoma did not occur in one Atm/
mTR/ or Atm/ mTR/ iG6 mouse that died (Fig. 4A). His-
topathological examination revealed lymphoma cells invading a va-
riety of organs including liver, kidney, bone marrow, and skeletal
Fig. 1. Short telomeres lead to germ cell deple-
tion in the absence of ATM. A, H&E-stained testis
sections (7–10 week-old) are shown for the geno-
types indicated at the top of each panel. The mouse
numbers are indicated at the left, and the body
weight of the mouse is indicated in parentheses.
Pictures were taken at 100 and 200. B, immun-
ofluorescent staining of GCNA1 in testis sections
labeled as in A. One representative sample is shown
for Atm/ mTR/ and Atm/ mTR/ mice.
Three representative samples are shown for
Atm/ mTR/ iG6 and Atm/ mTR/ iG6
mice. C, summary of testis morphology for each
genotype. Seminiferous tubules (100–200) from
each mouse were classified into four categories
based on H&E staining: normal, hypospermatogen-
esis, germinal arrest, and Sertoli cell only. The
percentages of PCNA and GCNA1 tubules in
immunofluorescent images were counted. The av-
erage number is shown. n, the number of mice for
each genotype.
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muscle in both Atm/ mTR/ and Atm/ mTR/ iG6 mice
(Supplementary Table 1). In addition to the lymphoid (T- and B-cell)
tumors, we also saw ovarian tubulostromal adenoma and squamous
cell carcinoma in the dying Atm/ mTR/ iG6 mice (Supplemen-
tary Table 1). The development of the non-T-cell tumors may be
attributable to the increased life span of these mice. A recent study
also found a decrease in thymic lymphoma in Atmy/y mTR/ mice
(31), but because the mouse model they used developed thymic
lymphoma at a very advanced age (52 weeks; Ref. 29), no increase in
life span was seen in that study (see “Discussion”).
The increase in survival of the mice was not attributable to the
change in growth rate because the growth rates of Atm/ mTR/
and Atm/ mTR/ iG6 mice were similar (Fig. 4B). To further
exclude the possibility that extended survival was attributable to the
proliferation defects in Atm/ mTR/ iG6 cells, we analyzed
BrdUrd incorporation in bone marrow cells from healthy, tumor-free
mice 7 to 10 weeks of age. No significant difference was found
between Atm/ mTR/ and Atm/ mTR/ iG6 mice (Fig. 4C).
Similar results were obtained for BrdUrd incorporation in thymocytes
and splenocytes from the same mice (data not shown). Thus, the
delayed incidence of thymic lymphoma in the Atm/ mTR/ iG6
mice was not attributable to general growth or proliferation defects.
Increased Apoptosis in Thymic Lymphoma of Atm/ mTR/
iG6 Mice. The delayed incidence of thymic lymphoma in the Atm/
mTR/ iG6 mice may result from the cooperative effect of short
telomeres and Atm deficiency on apoptosis as we found in the testis.
To examine apoptosis directly on thymic lymphoma sections, we used
the TUNEL assay. Tumors from Atm/ mTR/ iG6 mice (n  4)
exhibited significantly more TUNEL-positive cells than those from
Atm/ mTR/ mice (n  6; P  0.01; Fig. 5A). Moreover, unlike
Atm/ mTR/ thymic lymphomas that were easily cultured in vitro,
we were not able to establish cultures from Atm/ mTR/ iG6
tumors, even in the presence of IL-2 and other mitogens (data not
shown). Thus, increased apoptosis, presumably induced by telomere
dysfunction, may in part explain the decreased incidence and/or
increased latency of thymic lymphoma.
Telomere dysfunction often results in the appearance of anaphase
bridges through the formation of dicentric chromosomes (4, 42, 43).
To examine telomere dysfunction in tumors, we measured the an-
aphase bridge index in H&E stained sections of thymic lymphomas
from Atm/ mTR/ and Atm/ mTR/ iG6 mice (n  4 for each
genotype). There was a significant increase in the number of anaphase
bridges in the Atm/ mTR/ iG6 tumor sections (Fig. 5C). Over
90% of the anaphases from Atm/ mTR/ iG6 mice had at least one
bridge in contrast to 37% in the Atm/ mTR/ mice (P  0.00001;
Fig. 5, B and C). Thus, the increase in the number of anaphase bridges
in the Atm/ mTR/ iG6 tumors is consistent with the increased
telomere dysfunction.
To determine whether a decrease in tumor cell proliferation also
contributed to increased tumor latency, we measured the mitotic index
in H&E sections of thymic lymphomas. No significant difference in
the number of mitotic figures was seen between Atm/ mTR/ and
Atm/ mTR/ iG6 mice (n  4 for each; P  0.23; Fig. 5D). Thus,
although we saw no evidence of decreased proliferation of Atm/
mTR/ iG6 tumor cells, we did find evidence for increased telomere
dysfunction in these tumors.
Transformation of a Different T-Cell Type in Atm/ mTR/
iG6 Mice. Thymic lymphomas in Atm/ mice are positive for both
CD4 and CD8 immune T-cell lineage markers (26, 27). The double-
positive state of these tumors suggests that they arise early in T-cell
development before the transition to more mature, CD4 or CD8
single-positive cells. Tumors that arise in double-knockout mice
Atm/ p21/ and Atm/ p53/ (44) and the NBS1m/m mouse
(45) also are CD4CD8 double positive. Consistent with early
observations, we found that the thymic lymphomas in Atm/
mTR/ mice (n  5) were CD4CD8 with either high or low levels
of T-cell maturation markers CD3 (Fig. 6A) and TCR- chain (data
not shown; Ref. 46). Surprisingly, thymic lymphomas derived from
the Atm/ mTR/ iG6 mice (n  4) were CD8CD4 and did not
express TCR-/CD3 complex on their surface (Fig. 6A and data not
Fig. 2. ATM deficiency has no significant effect on telomere length. A, Q-FISH data
from Atm/ mTR/ are shown in blue. B, the data from A are shown overlayed with
telomere signals from Atm/ mTR/ metaphases shown in magenta. The mice exam-
ined are littermates from a cross of double heterozygotes. C, Q-FISH data from Atm/
mTR/ iG6 mice are shown in red. D, the Q-FISH signal from Atm/ mTR/ iG6
(green) is overlayed with the data from the Atm/ mTR/ iG6 littermates in red as in
C. Overlays are shown to highlight the small difference in telomere length seen in the
Atm/ mice. A total of 18 metaphases (3,000 telomere signals) were analyzed for each
genotype. The data represent three independent experiments with three mice for each
genotype. E, signal-free ends (SFE) were counted manually after overexposing the
telomere signal. A total of 75 metaphases from 4 independent Atm/ mTR/ mice, 88
metaphases from 5 independent Atm/ mTR/ mice, 73 metaphases from 5 independ-
ent Atm/ mTR/ iG6 mice, and 100 metaphases from 6 independent Atm/ mTR/
iG6 mice were analyzed. Frequency of SFE, the number of SFE per metaphase per mouse.
Bars, SD of the means from each mouse of that genotype.
Table 1 Summary of chromosome abnormalities
Mouse genotype





Atm/ mTR/ (n  4) 112 0 0 3 0
Atm/ mTR/ (n  5) 101 0 1 (1) 44 15
Atm/ mTR/ iG6 (n  5) 162 12 (100) 0 7 0
Atm/ mTR/ iG6 (n  6) 162 17 (35) 8 (14) 36 6
a One independent fusion event is one specific fusion event in a given mouse. Numbers in parentheses indicate total fusion events scored. p;p indicates p-arm-to-p-arm
Robertsonian-type fusion. q;q indicates q-arm-to-q-arm dicentric fusion.
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shown). Despite the lack of surface TCR-/CD3 expression, PCR
analysis using the primers specific for V5.1/J2.6 and V8.2/J2.6
revealed that these cells had undergone V(D)J rearrangement (Sup-
plementary Fig. 1). Thus, these CD4CD8 cells had apparently
progressed beyond the CD4CD8 double-negative stage. These
cells, however, are not derived from mature CD8 T cells but rather
may represent immature single-positive cells, a stage between the
double-negative and the double-positive stages (47–49). When cul-
tured in vitro, cells from the Atm/ mTR/ iG6 tumors did not
respond to a variety of mitogenic stimuli, including phorbol myristate
acetate, ionomycin, and IL-2 (data not shown), consistent with their
being intermediate, immature, single-positive cells (47, 48, 50). Fur-
thermore, after 24 h of in vitro culture, tumor cells differentiated into
CD8CD4low/ T cells with increased expression of CD3 (Fig. 6B),
suggesting that these CD8 cells from Atm/ mTR/ iG6 mice are
at an earlier developmental stage than the double-positive cells (47,
48, 51, 52).
To exclude the possibility that in the Atm/ mTR/ iG6 mice
T-cell development was blocked at the CD8 immature, single-
positive stage, we examined T-cell types in thymuses of healthy mice
that were 7–10 weeks of age. The percentages of double-positive,
double-negative, and single-positive (CD4 or CD8) thymocytes
Fig. 3. Increased independent fusion events in the Atm/ mTR/ iG6 mice. A and
B, two representative unique fusion events in the Atm/ mTR/ iG6 mice indicated by
arrowheads: A, single q-arm fusion f(1q;Xq); B, p-arm-to-p-arm fusion f(5p;17p). C,
summary of independent fusion events. Number indicates independent fusion events
scored. Number in the parentheses indicates total events scored for the independent fusion
event from each genotype. n is the number of mice for each genotype.
Fig. 4. Decreased and delayed incidence of thymic lymphoma in Atm/ mTR/ iG6
mice. A, Kaplan-Meier survival curve of Atm/ mTR/, Atm/ mTR/ iG6, Atm/
mTR/ iG6, and Atm/ mTR/ mice is shown. Tick marks indicate the current age of
individual surviving mice. , the mouse died without thymic lymphoma. n indicates the
number of mice. B, similar growth rates were observed between Atm/ mTR/ iG6 and
Atm/ mTR/ mice. The body weight of each cohort was followed over a period of 24
weeks. Each data point represents at least 7 individual mice, except for Atm/ mTR/
mice from week 20 only represents 1–2 surviving mice. A and B share the same legend.
C, BrdUrd analysis of the bone marrow cells from young tumor-free mice shows no
difference in cellular proliferation among four different genotypes. The boxed area refers
to the BrdUrd cells that have been through or are still in S-phase. The numbers indicate
the percentage of BrdUrd cells in the population. The data represent two independent
experiments.
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were similar between Atm/ mTR/ and Atm/ mTR/ iG6 mice
(Fig. 6C). Similarly, in the spleen, the percentages of mature CD4
and CD8 single-positive T cells were not significantly different
between Atm/ mTR/ and Atm/ mTR/ iG6 mice (data not
shown). Therefore, there is not a developmental block in the Atm/
mTR/ iG6 T cells at the transition from CD4CD8 immature,
single-positive to CD4CD8 double-positive cells. Thus, we con-
clude that the tumors in the Atm/ mTR/ iG6 mice likely arise
from an earlier developmental stage of the T-cell lineage than in the
Atm/ mTR/ mice.
DISCUSSION
Telomere dysfunction is thought to mimic a DNA double-strand
break and activate cell cycle arrest or apoptosis (53, 54). In cultured
human cells, the cellular response to telomere dysfunction is both p53
and ATM dependent (8). Our study and the recent one by Wong et al.
(31) indicate that Atm deficiency and short telomeres lead to in-
creased apoptosis in mice, indicating that Atm is not required for cell
death induced by progressive telomere shortening. The discrepancy in
the requirement of Atm for apoptosis triggered by dysfunctional
telomeres could be attributable to the differences in human versus
mouse cells (55), the use of cultured cell lines versus in vivo models,
or a mechanistic difference in how loss of telomere function through
progressive telomere shortening versus loss of telomere binding pro-
teins are recognized by the cell. If Atm is not required for apoptosis
in response to telomere dysfunction, then other damage sensors such
as Atr (56, 57) are likely to be involved. Recent data show that Atm
and Atr act in distinct but partially overlapping pathways in response
to specific types of DNA damage. Atm is more specialized for
response to ionizing radiation, whereas Atr responds to a broad range
of damage including ionizing radiation, UV, and stalled replication
forks (58). In addition, unlike Atm, Atr binds to asynapsed chromo-
somes during meiosis (59, 60), suggesting that Atm and Atr may play
a different role in recognition of DNA damage. Recent work in yeast
suggests that Mec1 (Atr homolog), but not Tel1 (Atm homolog), is
required for the cell cycle arrest of telomerase-deficient cells (61, 62).
The cooperative effect of Atm deficiency and short telomeres could
be attributable to several causes. Telomere dysfunction sensitizes cells
to ionizing radiation (63, 64), suggesting that the total amount of
damage determines the cellular response. Thus, the increased apo-
ptosis may result from the sensitizing effect of chromosome breaks
that are present in the absence of Atm on the response to short
telomeres. Alternatively, Atm loss may directly impair the residual
protective function of short telomeres leading to increased telomere
dysfunction. Our data support the latter model. In the Atm/ mTR/
iG6 and not the Atm/ mTR/ iG6 lymphocytes, there was an
increase in end-to-end fusions consistent with increased telomere
dysfunction but not with an additive effect of DNA breaks. We saw no
increase in chromosome breaks in lymphocytes from Atm/ mTR/
iG6 mice compared with Atm/ mTR/ mice (Table 1). Further-
more, Atm clearly plays a direct role in telomere function in yeast.
Absence of the Atm homolog Tel1 causes telomere shortening (20,
21), and loss of both the Atm and Atr homologs inhibits the ability of
telomerase to elongate telomeres (23, 24). Recent work in yeast
indicates a direct role for Tel1 in telomere protection (65). Thus, Atm
may function at telomeres through direct binding to short telomeres,
phosphorylation of telomere-binding proteins, or through a less direct
regulation of the function of other telomere proteins. We propose that
in the absence of Atm, the loss of this protection drives short te-
lomeres to become prematurely dysfunctional without further short-
ening. The protection provided by Atm is not essential for long
telomeres, perhaps because of the ample presence of telomere-binding
proteins, such as TRF1, TRF2, or Pot1.
Several lines of evidence suggest that telomere dysfunction can
limit tumor growth: (a) inhibition of telomerase in human cancer cells
in culture leads to cell death (66–70); (b) double mutants of telom-
erase and Ink4a/Arf/ resulted in a reduction of tumors in the
late-generation mice with short telomeres (6); (c) telomere dysfunc-
tion enhances the chemotherapeutic effect on cancer cells (71); and
(d) double-mutant APCmin mTR/ late-generation mice show in-
creased tumor initiation (microscopic adenomas) but decreased pro-
gression of the tumors into macroscopic adenomas (4). In support of
the role of short telomeres in blocking tumor progression, this study
and the work by Wong et al. (31) found a decrease in thymic
lymphoma incidence in the Atm mTR double null mice. In addition,
our double-mutant mice had a significant survival advantage. This
difference in overall survival is likely attributable to the differing
genetic background and/or mutagenesis strategies used in generating
the Atm single-mutant mice (26, 29).
The observed reduction in thymic lymphoma incidence could be
attributable to several different mechanisms: increased apoptosis,
decreased tumor cell growth, delayed tumor initiation, or a combina-
tion of these factors. Our data suggest that the increased apoptosis
attributable to the cooperative effect of short telomeres and Atm loss
plays a major role in tumor reduction. Similar to the increased
apoptosis seen in the germ cells in Atm/ mTR/ iG6 mice, we
found increased apoptosis in the Atm/ mTR/ iG6 lymphomas
compared with Atm/ mTR/ lymphomas. The significant increase
Fig. 5. Increased anaphase bridge index and apoptosis in the thymic lymphoma of
Atm/ mTR/ iG6 mice. A, TUNEL cells were counted in four low power fields of
each cohort (6 mice for Atm/ mTR/ and 4 mice for Atm/ mTR/ iG6). The
average number of total TUNEL cells for each sample is shown. B and C, anaphases
with anaphase bridges were counted in ten high power fields of each mouse (4 mice/
cohort). Two representative images for each cohort are shown in B. White arrowhead, the
anaphase with spanning bridges; red arrowhead, the normal anaphase. The anaphase
bridge index represents the ratio of anaphases with at least 1 bridge to total number of
anaphases counted in each mouse. A total of 77 and 50 anaphases were counted in Atm/
mTR/ and Atm/ mTR/ iG6 mice, respectively. D, cells undergoing mitosis with
condensed chromatin were counted in 10 high-power fields of each mouse (4 mice/
cohort). Bars represent the SD of the means from each mouse of each cohort.
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in anaphase bridges in the Atm/ mTR/ iG6 lymphomas indicates
ongoing telomere dysfunction in the tumors. In contrast, the mitotic
index in Atm/ mTR/ iG6 lymphomas was similar to Atm/
mTR/ mice, suggesting that decreased proliferation did not play a
major role.
A decrease in tumor initiation might also contribute to the de-
creased latency of death from thymic lymphoma in Atm/ mTR/
iG6 mice. The switch in cell type from the CD4CD8 double-
positive cells in Atm/ to CD8 immature, single-positive cells in
Atm/ mTR/ iG6 lymphomas suggests that tumors arise in a
different cell population in Atm/ mTR/ iG6 mice. T-cell devel-
opment progresses from a CD4CD8 double-negative stage through
a CD8 immature, single-positive stage to CD4CD8 double-
positive and further to mature CD4 or CD8 single-positive cells
(46). The CD8 immature, single-positive cells represent 1–2% of
developing T cells in thymus and are actively cycling (47–49, 72).
Fig. 6. Thymic lymphomas from Atm/ mTR/ iG6 mice are derived from CD8 immature, single-positive T cells. A and B, flow cytometric analysis on thymocytes and thymic
lymphoma cells. A, fresh thymocytes from one control Atm/ mTR/ mouse and Atm/ mTR/ iG6 mouse and thymic lymphomas derived from two Atm/ mTR/ and Atm/
mTR/ iG6 mice were stained for CD4, CD8, and CD3. The CD4CD8 double-positive (DP) and CD8 single-positive (SP) cells were gated for expression of CD3. The percentages
of DP, SP, and CD3 cells are indicated in each panel. B, thymic lymphomas from Atm/ mTR/ iG6 mice cultured for 24 h in vitro and stained for CD4, CD8, and CD3. The
CD4CD8 double-positive (DP) and CD8 single-positive (SP) cells were gated for expression of CD3. C, T-cell development in the Atm/ mTR/ iG6 mice was similar to wild
type. Thymocytes from tumor-free mice, 7–10 weeks of age, of four different genotypes were examined for CD4 and CD8 expression. The genotype is indicated on top of each panel.
The percentage of each population is shown in each quadrant.
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The developmental transition from immature, single-positive cells to
double-positive cells involves a large clonal expansion (46). If the
cycling and the expansion of immature, single-positive cells in
Atm/ mTR/ iG6 mice are limited by telomere dysfunction, tumor
initiation at the double-positive stage may be inhibited. Eventually
however, sufficient instability may accumulate in the CD8 immature,
single-positive cells and lead to tumor initiation. The delay in initia-
tion may contribute to the increased latency of death attributable to
thymic lymphoma in Atm/ mTR/ iG6 mice. Further analysis of
the TCR rearrangements in these tumors will help pinpoint the spe-
cific subpopulation of cells that are transformed.
The increased survival of the Atm/ mTR/ iG6 mice provides
a powerful model for the further study of A-T disease. In A-T patients,
tumors account for only 10–15% of deaths, whereas the majority die
from infections attributable to immunodeficiency (73). Although thy-
mic lymphoma is the only tumor type seen in the Atm/ mouse, A-T
patients develop a variety of tumors including B-cell tumors and
non-lymphoid tumors, such as ovarian, uterine, and stomach tumors
(73, 74). The short life spans of the Atm/ mice likely contribute to
the phenotype difference with human A-T patients. The significant
increase in the life span of the Atm/ mTR/ iG6 mouse will allow
examination of the older Atm/ mTR/ iG6 mice and may thus
provide insights into other clinical features of A-T patients.
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